The AI in precision medicine market is experiencing significant growth, driven by the increasing global prevalence of chronic and genetic disorders, which has heightened the demand for personalized ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

Advances have made cancer therapies more effective through targeting specific molecules. Companion diagnostics (CDx) are ...

A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid ...

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence for healthcare, has announced the launch of Fuses, a ...

“For certain diseases, genomic or proteomic alterations may not be evident, whereas metabolic disturbances are often more ...

Today, cancer stage and tumor size tell which patients will receive adjuvant chemotherapy. But the rise of biomarker testing ...

Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

In the past, most targeted drug development efforts relied on single biomarkers, but cancer is far more complex. BostonGene’s ...

Carnegie Mellon University researchers are using personalized models to decode how cancer behaves in individual ...

Danaher Corporation DHR recently partnered with AstraZeneca PLC AZN to develop and market novel diagnostic tools aimed at ...